{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:48:37Z","timestamp":1791643717474,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.msard.2022.103527","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T12:07:53Z","timestamp":1642680473000},"page":"103527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Serum molecular biomarkers in neuromyelitis optica and multiple sclerosis"],"prefix":"10.1016","volume":"59","author":[{"given":"Cong-Cong","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Qing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Qiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianne","family":"Petritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Ming","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo-Pan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.103527_bib0001","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1038\/s41467-020-16625-7","article-title":"Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica","volume":"11","author":"Agasing","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2022.103527_bib0002","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2147\/NDT.S185336","article-title":"Cytokines and chemokines expression in serum of patients with neuromyelitis optica","volume":"15","author":"Ai","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.msard.2022.103527_bib0003","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ana.26067","article-title":"Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker","volume":"89","author":"Aktas","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2022.103527_bib0004","article-title":"Treatment with anti-EGF ab ameliorates experimental autoimmune encephalomyelitis via induction of neurogenesis and oligodendrogenesis","volume":"2014","author":"Amir-Levy","year":"2014","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.msard.2022.103527_bib0005","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","article-title":"Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab","volume":"23","author":"Araki","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.msard.2022.103527_bib0006","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2022.103527_bib0007","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.molimm.2017.07.004","article-title":"IL-17B: a new area of study in the IL-17 family","volume":"90","author":"Bie","year":"2017","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.msard.2022.103527_bib0008","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2022.103527_bib0009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2018.05.014","article-title":"Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: a multicenter study in South China","volume":"321","author":"Chen","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2022.103527_bib0010","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1212\/WNL.0b013e318296ea22","article-title":"Seronegative NMO: a sensitive AQP4 antibody test clarifies clinical features and next challenges","volume":"80","author":"Fujihara","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103527_bib0011","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1096\/fj.09-141978","article-title":"Cellular mechanisms of IL-17-induced blood-brain barrier disruption","volume":"24","author":"Huppert","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.msard.2022.103527_bib0012","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/01.wnl.0000256822.01222.bd","article-title":"NMO-IgG in the diagnosis of neuromyelitis optica","volume":"68","author":"Jarius","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103527_bib0013","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1352458511431728","article-title":"Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature","volume":"18","author":"Jarius","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.103527_bib0014","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ncpneuro0764","article-title":"Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica","volume":"4","author":"Jarius","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.msard.2022.103527_bib0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. neuroinflamm."},{"key":"10.1016\/j.msard.2022.103527_bib0016","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol."},{"key":"10.1016\/j.msard.2022.103527_bib0017","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/rheumatology\/ket309","article-title":"Neutrophils produce interleukin-17B in rheumatoid synovial tissue","volume":"53","author":"Kouri","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.msard.2022.103527_bib0018","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2022.103527_bib0019","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet N. Am. Ed."},{"key":"10.1016\/j.msard.2022.103527_bib0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jneuroim.2013.01.012","article-title":"High and dysregulated secretion of epidermal growth factor from immune cells of patients with relapsing-remitting multiple sclerosis","volume":"257","author":"Levy","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2022.103527_bib0021","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1080\/00207454.2016.1259226","article-title":"Aquaporin-4 antibody in neuromyelitis optica: re-testing study in a large population from China","volume":"127","author":"Long","year":"2017","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.msard.2022.103527_bib0022","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.msard.2022.103527_bib0023","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/0024-3205(86)90298-5","article-title":"Human urinary epidermal growth factor: effects of age, sex and female endocrine status","volume":"39","author":"Mattila","year":"1986","journal-title":"Life Sci."},{"key":"10.1016\/j.msard.2022.103527_bib0024","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0960-8966(01)00250-4","article-title":"Expression of IL-17B in neurons and evaluation of its possible role in the chromosome 5q-linked form of Charcot-Marie-Tooth disease","volume":"12","author":"Moore","year":"2002","journal-title":"Neuromuscul. Disord. NMD"},{"key":"10.1016\/j.msard.2022.103527_bib0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1684\/ecn.2013.0330","article-title":"Correlations between concentrations of interleukin (IL)-17A, IL-17B and IL-17F, and endothelial cells and proangiogenic cytokines in systemic lupus erythematosus patients","volume":"24","author":"Robak","year":"2013","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.msard.2022.103527_bib0026","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature12880","article-title":"Intranasal epidermal growth factor treatment rescues neonatal brain injury","volume":"506","author":"Scafidi","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.msard.2022.103527_bib0027","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.neuroscience.2015.04.020","article-title":"Low levels of cobalamin, epidermal growth factor, and normal prions in multiple sclerosis spinal cord","volume":"298","author":"Scalabrino","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.msard.2022.103527_bib0028","doi-asserted-by":"crossref","first-page":"19167","DOI":"10.1074\/jbc.M910228199","article-title":"A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity","volume":"275","author":"Shi","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.msard.2022.103527_bib0029","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jnnp-2011-300434","article-title":"Sera from neuromyelitis optica patients disrupt the blood-brain barrier","volume":"83","author":"Shimizu","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2022.103527_bib0030","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.msard.2022.103527_bib0031","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2022.103527_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.103527_bib0033","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.103527_bib0034","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1007\/s00415-009-5274-4","article-title":"Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis","volume":"256","author":"Uzawa","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.103527_bib0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bpa.12097","article-title":"Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications","volume":"24","author":"Uzawa","year":"2014","journal-title":"Brain Pathol."},{"key":"10.1016\/j.msard.2022.103527_bib0036","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/glia.23037","article-title":"Epidermal growth factor preserves myelin and promotes astrogliosis after intraventricular hemorrhage","volume":"64","author":"Vinukonda","year":"2016","journal-title":"Glia"},{"key":"10.1016\/j.msard.2022.103527_bib0037","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103527_bib0038","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103527_bib0039","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurology."},{"key":"10.1016\/j.msard.2022.103527_bib0040","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2022.103527_bib41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/1352458513499420","article-title":"Comparison of deep gray matter lesions on magnetic resonance imaging among adults with acute disseminated encephalomyelitis, multiple sclerosis, and neuromyelitis optica","volume":"20","author":"Zhang","year":"2014","journal-title":"Mult Scler"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822000426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822000426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:01:00Z","timestamp":1761901260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822000426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":41,"alternative-id":["S2211034822000426"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103527","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum molecular biomarkers in neuromyelitis optica and multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103527"}}